WuXi Biologics (Cayman) (SEHK:2269) - 주가, 뉴스 및 분석

2269 주식 개요

는 중화인민공화국, 북미, 유럽, 싱가포르, 일본, 한국, 호주에서 생물학적 제제 산업을 위한 생물학적 제제 발견, 개발 및 제조를 위한 엔드투엔드 솔루션과 서비스를 제공하는 투자 지주 회사입니다. 자세한 내용

2269 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	3/6
과거 실적	2/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 61.9% 에서 거래

수익은 매년 17.91% 증가할 것으로 예상됩니다.

위험 분석

이익 마진 (15.4%) 작년보다 낮습니다 (25.1%)

WuXi Biologics (Cayman) Inc. 경쟁사

WuXi XDC Cayman

SEHK:2268

HK$29.9b

Frontage Holdings

SEHK:1521

HK$2.1b

CSPC Pharmaceutical Group

SEHK:1093

HK$59.8b

Sino Biopharmaceutical

SEHK:1177

HK$60.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 WuXi Biologics (Cayman)
과거 주가
현재 주가	HK$15.02
52주 최고치	HK$49.70
52주 최저치	HK$10.14
베타	0.61
11개월 변경	-8.97%
3개월 변경 사항	26.01%
1년 변경 사항	-68.21%
33년 변화	-86.42%
5년 변화	-50.73%
IPO 이후 변화	59.50%

최근 뉴스 및 업데이트

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26

Recent updates

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Sep 12

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15

주주 수익률

	2269	HK Life Sciences	HK 마켓
7D	-12.3%	-8.1%	-5.3%
1Y	-68.2%	-57.8%	11.3%

수익률 대 산업: 2269 지난 1년 동안 -57.8 %를 반환한 Hong Kong Life Sciences 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: 2269 지난 1년 동안 11.3 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 2269's price volatile compared to industry and market?
2269 volatility
2269 Average Weekly Movement	12.5%
Life Sciences Industry Average Movement	14.4%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.1%
10% least volatile stocks in HK Market	4.2%

안정적인 주가: 2269 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 2269 의 주간 변동성( 12% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2014	12,435	Chris Chen	www.wuxibiologics.com

투자 지주 회사인 우시 바이오로직스(케이맨)는 중화인민공화국, 북미, 유럽, 싱가포르, 일본, 한국, 호주에서 바이오로직스 산업을 위한 바이오로직스 발견, 개발, 제조를 위한 엔드투엔드 솔루션과 서비스를 제공합니다. 이 회사는 두 가지 부문으로 운영됩니다: 바이오로직스와 XDC. 이 회사는 개념에서 임상시험계획(IND)에 이르는 생물학적 발견을 위한 솔루션 제품군을 제공하며, 계약 연구, 개발 및 제조 조직 플랫폼인 WuXiBody, SDArBodY, T 세포 인게이저, 단일 B 세포 복제 기술, WuXia, WuXiUP, WuXiUI 및 WuXiHigh를 통해 CMC 및 다운스트림 프로세스 개발을 원활하게 이행할 수 있는 서비스를 제공합니다.

WuXi Biologics (Cayman) Inc. 기본 사항 요약

WuXi Biologics (Cayman) 의 수익과 매출은 시가총액과 어떻게 비교하나요?
2269 기본 통계
시가총액	HK$61.65b
수익(TTM)	HK$2.83b
수익(TTM)	HK$18.43b

21.7x

P/E 비율

3.3x

P/S 비율

2269 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
2269 손익 계산서(TTM)
수익	CN¥17.12b
수익 비용	CN¥10.50b
총 이익	CN¥6.62b
기타 비용	CN¥3.99b
수익	CN¥2.63b

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.64
총 마진	38.66%
순이익 마진	15.38%
부채/자본 비율	4.8%

2269 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

2269 주식 개요

보상

위험 분석

WuXi Biologics (Cayman) Inc. 경쟁사

SEHK:2268

HK$29.9b

SEHK:1521

HK$2.1b

SEHK:1093

HK$59.8b

SEHK:1177

HK$60.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Less than half of directors are independent

Consensus EPS estimates fall by 18%

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 16%

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Consensus revenue estimates fall by 14%

Investor sentiment deteriorates as stock falls 28%

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 20% undervalued

Board Member recently sold HK$25m worth of stock

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023